Skip to main content
SpringerLink
Log in

Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS

  • Clinical and Epidemiological Studies
  • Originalia
  • Published:
Infection Aims and scope Submit manuscript

Summary

A randomized, double-blind trial compared treatment with the immune modulator WF10 (ten patients) and placebo (nine patients) administered in cycles over 3 months among individuals with advanced AIDS. There were no notable clinical adverse events; changes in hematologic and chemistry values were comparable in the two groups. In both groups, median HIV-RNA PCR values remained stable. Immunologic variables showed a consistent tendency to increase in the WF10 group and to decrease in the control group, with significant differences between groups for median WBC, lymphocyte, CD19, and CD35 values. Ten infections occurred in the control group, four of which werePneumocystis carinii pneumonia (PCP), and three in the WF10 group none of which was PCP. Five patients in the control group were hospitalized during the trial for a total of 53 days; no patients in the WF10 group were hospitalized. Over a subsequent 9-months follow-up, six patients from the control group and one from the WF10 group died. These results indicate that WF10 administration appears safe, may enhance immunologic function, and unlike other macrophage-activating cytokines does not increase HIV expression in this patient population. Further studies of WF10 in larger patient populations are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kühne, F. W.: Die erwünschte Sauerstoffaktivierung, dokumentiert am Beispiel der Wundheilung: der Weg zur Oxoferin-Therapie. In:Elstner E. F., Bors W., Wilmanns W. (eds.): Reaktive Sauerstoffspezies in der Medizin. Springer Verlag, Berlin 1986, pp. 5–15.

    Google Scholar 

  2. Ullmann, U., Kühne, F. W.:In vitro investigations on the antibacterial action and the influence on the phagocytic chemiluminescence of tetrachlordecaoxide—a new non-metallic oxygen complex. Infection 12 (1984) 225–229.

    Article  PubMed  CAS  Google Scholar 

  3. Woerly, G., Lombard, Y., Poindron, P., Stahl, K. W.: Candida phagocytosis of murine macrophages: enhancement by a novel type of oxidant. In:Mauri C., Rizzo S. C., Ricevuti G. (eds.): The biology of phagocytosis in health and disease. Pergamon Press, Oxford 1987, pp. 109–112.

    Google Scholar 

  4. Ennen, J., Werner, K., Kühne, F. W., Kurth, R.: Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlordecaoxygen. AIDS 7 (1993) 1205–1212.

    Article  PubMed  CAS  Google Scholar 

  5. Gillissen, G., Kühne, F. W., Breuer-Werle, M., Melzer, B., Ostendorp, H.: Increased resistance towards two systemic experimental infections by tetrachlorodecaoxygen anion complex. Arzneimittelforschung/Drug Research 36 (1986) 1778–1782.

    CAS  Google Scholar 

  6. Hänsel, M., Poindron, P., Stahl, K. W.: Modulation of leucocyte growth in intraepidermal skin blisters. Skin Pharmacol. 1 (1988) 64.

    Google Scholar 

  7. Müller-Klieser, W., Vaupel, P.: Improvement of tumour-spheroid oxygenation by tetrachlorodecaoxygen. Int. J. Radiat. Oncol. Biol. Phys. 13 (1987) 49–54.

    Google Scholar 

  8. Ivankovic, S., Kempf, S. R.: Regenerative effects of tetrachlorodecaoxide in BD IX rats after total-body δ-irradiation. Radiat. Res. 115 (1988) 115–123.

    Article  PubMed  CAS  Google Scholar 

  9. Breiter, N., Sassy, T., Trott, K. R.: Tetrachlorodecaoxygen anion complex treatment after localised x irradiation of the rat colon. Br. J. Radiol. 62 (1989) 381–383.

    Article  PubMed  CAS  Google Scholar 

  10. Milas, L.: Therapeutic potential of using radioprotective agents for minimising radiation injury of normal tissue. Presented at the International Symposium on Tissue Repair, 7 December 1990, Pattaya, Thailand.

  11. Mason, K. A., Murphy, S., Milas, L.: Stimulation of hematopoietic cell recovery by tetrachlordecaoxide in sublethally irradiated mice. Radiat. Res. 136 (1993) 229–235.

    Article  PubMed  CAS  Google Scholar 

  12. Günther, H.-J., Hinz, J.: Die Beeinflussung von Wundheilungsstörungen und Wundinfektionen mit Oxoferin. Ergebnisse einer Phase IV Studie in der Klinik. In:Macher, E., Knop, J., Brocker, E. B. (eds.) Jahrbuch der Dermatologie 1989/1990. Biermann Verlag, Münster 1990, pp. 141–148.

    Google Scholar 

  13. Teepe, R. G. C., Koebrugge, E. J., Löwik, C. W. G. M., Petit, P. L. C., Bosboom, R. W., Twiss, I. M., Boxma, H., Vermeer, B. J., Ponec, M.: Cytotoxic effects of antimicrobial and antiseptic agents on human keratinocytesin vitro. J. Trauma 35 (1993) 8–19.

    Article  PubMed  CAS  Google Scholar 

  14. Crowe, S. M.: Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection. Aust. N Z J Med. 25 (1995) 777–783.

    PubMed  CAS  Google Scholar 

  15. Kühne, F. W.: A new anti-HIV agent combining immunomodulation with antiretroviral activity. Presented at the 4th Annual Houston Conference on AIDS in America, 20 March 1992, Houston, Texas.

  16. Bodin, L., Tansuphaswadikul, S., Kühne, F. W., Rungsiwongse, J., Likanosakul, S., Eampokalap, B.: Preliminary evaluation of the efficacy and tolerance of WF10 (TCDO) i.v. solution as adjunctive therapy in the management of adult patients with symptomatic human immunodeficiency virus infection. Presented at the 2nd National Conference on AIDS, 21 May 1992, Jomtien-Pattaya, Thailand.

  17. Busch, H. W., Christensen, S., Reichelt, D., Jahn, S., Zidek, W.: Treatment of HIV-infected patients with advanced symptomatic disease with WF10 solution (TCDO). Poster presented at the 10th International Conference on AIDS, 7–12 August 1994, Yokahama, Japan.

  18. Somsit, T.: Long-term safety and efficacy of WF10 (TCDO) i.v. solution as adjunctive therapy in the management of adult patients with symptomatic human immunodeficiency virus infection. Presented at the International Workshop on Immunomodulation: a new approach to the promotion of immune functions in health and diseases. 17 May 1997, Hua Hin, Thailand.

  19. Kempf, S. R., Blaszkiewitz, K., Reim, M., Ivankovic, S.: Comparative study on the effects of chlorite oxygen reaction product TCDO (tetrachlorodecaoxygen) and sodium chlorite solution (NaClO2) with equimolar chlorite content on bone marrow and peripheral blood of BDIX rats. Drugs Exp. Clin. Res. 19 (1993) 165–174.

    PubMed  CAS  Google Scholar 

  20. Hatz, R. A., Kelley, S. F., Ehrlich, H. P.: The tetrachlorodecaoxygen complex reverses the effect of cortisone on wound healing. Plast. Reconstr. Surg. 84 (1989) 952–959.

    Article  Google Scholar 

  21. Hinz, H., Hautzinger, H., Stahl, K. W.: Rationale for and results from a randomised double-blind trial of tetrachlorodecaoxygen anion complex in wound healing. Lancet i (1986) 825–828.

    Article  Google Scholar 

  22. Koyanagi, Y., O'Brien, W. A., Zhao, J. Q., Golde, D. W., Gasson, J. C., Chen, I. S. Y.: Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 241 (1988) 1673–1675.

    Article  PubMed  CAS  Google Scholar 

  23. Kaplan, L. D., Kahn, J. O., Crowe, S., Northfelt, D., Neville, P., Grossberg, H., Abrams, D. I., Tracey, J., Mills, J., Volberding, P. A.: Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin’s lymphoma: results of a randomized trial. J. Clin. Oncol. 9 (1991) 929–940.

    PubMed  CAS  Google Scholar 

  24. Weissman, D., Fauci, A. S.: Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infection. Clin. Microbiol. Rev. 10 (1997) 358–367.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Div. Of Infectious Diseases, Dept. of Medicine, Vanderbilt School of Medicine A-1124 MCN, 37232-2637, Nashville, TN, USA

    S. P. Raffanti M. D.

  2. Dept. of Preventive Medicine, Vanderbilt School of Medicine, A-1124 MCN, 37232-2637, Nashville, TN, USA

    W. Schaffner M. D.

  3. Dept. of Preventive Medicine, Vanderbilt School of Medicine, A-1124 MCN, 37232-2637, Nashville, TN, USA

    C. F. Federspiel Ph. D.

  4. Comprehensive Care Center, 345 24th Ave. North, Nashville, TN, USA

    R. B. Blackwell R. N.

  5. OXO Chemie, Wanzleben, Germany

    O. A. Ching M. D. & F. -W. Kühne Ph.D.

Authors
  1. S. P. Raffanti M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Schaffner M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. F. Federspiel Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. B. Blackwell R. N.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. O. A. Ching M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. -W. Kühne Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raffanti, S.P., Schaffner, W., Federspiel, C.F. et al. Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Infection 26, 202–207 (1998). https://doi.org/10.1007/BF02962364

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02962364

Keywords

Search

Navigation